US pediatric group breaks with CDC advice, recommends COVID vaccines for young children
The AAP, in tandem with multiple other professional medical associations, previously decried a May announcement made by Kennedy Jr. that the COVID-19 vaccine would no longer be included in the Centers for Disease Control's recommended immunizations for healthy children and pregnant women, a move that went against previous expert guidance and bypassed the normal scientific review process.
The AAP, a professional organization of over 65,000 board-certified pediatricians dedicated to advancing children's medicine, said in a June 26 statement that it would "continue to publish its own evidence-based recommendations and schedules," as the creation of federal immunization policy is 'no longer a credible process."
Kennedy Jr. drew further ire from medical communities when he fired all 17 original members of the Advisory Committee on Immunization Practices, the committee of health experts that provides guidance on vaccine use to the CDC, replacing them with members that critics have called unqualified. Some of the members, like Kennedy Jr., have a history of anti-vaccine advocacy and involvement in anti-vaccine groups.
Here's what to know about the new AAP guidance and how it differs from federal guidelines.
What is the AAP guidance on COVID-19 vaccines for children?
The AAP schedule lists which vaccines children should get at certain ages and provides updated guidance on influenza, RSV, and COVID-19 immunizations for children and adolescents from birth to age 18.
The schedule recommends that all children between six months and 23 months receive the latest COVID-19 vaccine to reduce the chance of serious illness. Children and adolescents aged 2 to 18, without other high-risk factors like immunosuppression, can receive and should be offered the vaccine if they were not previously immunized, according to the guidance.
Children, teens, and adults alike who are at increased risk of serious infection should receive the vaccine if they have not already, AAP said, adding that its recommendation differed from the CDC, which it said is now staffed with people who have a history of spreading vaccine misinformation.
"The AAP will continue to provide recommendations for immunizations that are rooted in science and are in the best interest of the health of infants, children, and adolescents," AAP President Dr. Susan J. Kressly, MD, said in a statement. "Pediatricians know how important routine childhood immunizations are in keeping children, families and their communities healthy and thriving."
What is the federal guidance on COVID-19 vaccines for children?
The CDC did not go as far as completely removing COVID-19 vaccination from its immunization schedule despite Kennedy Jr.'s insistence. Instead, the agency changed its language from recommending the vaccine annually to suggesting parents consult with their child's physician on whether to vaccinate.
Kennedy Jr. previously said that the CDC planned only to recommend the COVID vaccine for people over the age of 65 and those at high personal risk of infection, though the agency's website still contains information recommending it for everyone over the age of six months. A notice on the top webpages on the topic reads, "COVID-19 vaccine recommendations have recently been updated for some populations. This page will be updated to align with the updated immunization schedule," as of Aug. 19.
This change to whom the vaccine is recommended could make it harder for others who want the COVID-19 vaccine to get it, experts warned. Since insurance coverage typically follows federal recommendations, anyone who wants the shot but isn't on the CDC's recommendation list may have to pay the price out of pocket
HHS Communications Director Andrew Nixon defended the decision in a statement to USA TODAY, accusing the AAP, which receives funding from pharmaceutical companies like Pfizer, of failing to have proper conflict-of-interest safeguards in place.
"By bypassing the CDC's advisory process and freelancing its own recommendations, while smearing those who demand accountability, the AAP is putting commercial interests ahead of public health and politics above America's children," Nixon said.
Kennedy Jr. shared a separate response on social media on Aug. 19, pointing out that the agency's top donors are four companies that "make virtually every vaccine on the CDC recommended childhood vaccine schedule" and saying that the AAP recommendations are "corporate-friendly" and may "promote commercial ambitions of AAP's Big Pharma benefactors" instead of public health.
"AAP should also be candid with doctors and hospitals that recommendations that diverge from the CDC's official list are not shielded from liability under the 1986 Vaccine Injury Act," his post concluded.
USA TODAY reached out to AAP for comment on Aug. 19 but has not received a response.
The new Advisory Committee on Immunization Practices didn't vote on COVID-19 vaccine recommendations when they met in June and are expected to reconvene in "September/October," according to the CDC.
The FDA has signaled intentions to revoke the Pfizer COVID-19 shot for young, healthy children. In early August, HHS announced that it would pull $500M in funding from mRNA vaccine research and development.
This article originally appeared on USA TODAY: Young kids should receive COVID vaccine despite CDC advice: AAP
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
KROMATID Announces Successful Close of $8 Million Series C Funding Round, Exceeding Growth Capital Goals
Funding positions KROMATID for accelerated growth in genomic analysis and gene editing technologies BOULDER, Colo., Aug. 20, 2025 /PRNewswire/ -- KROMATID, a leader in next-generation genomic structural analysis, today announced the successful close of its Series C funding round, raising a total of $8 million and surpassing its targeted capital goals. The most recent tranche of the round contributed $3.8 million. The round was led by BroadOak Capital Partners, with participation from both existing and new strategic investors. The capital from this Series C close will fuel expansion of KROMATID's proprietary platforms for detecting chromosomal structural rearrangements, scale operations to meet growing global demand, and advance strategic partnerships with pharmaceutical and academic leaders in cell and gene therapy. "We are thrilled to have achieved our funding goal, which is a testament to the confidence our investors have in our vision and the unique capabilities of our technology," said Jim Chomas, CEO of KROMATID. "This investment enables us to scale faster, innovate further, and continue delivering the genomic insights that help bring life-changing therapies to patients." "KROMATID has built a differentiated platform that provides accurate, high-resolution analysis of genomic integrity, one of the most pressing needs in the rapidly expanding gene and cell therapy industry," said Bill Snider, Partner at BroadOak Capital Partners. "We are proud to continue our partnership as they enter their next phase of growth." Over the next 12–18 months, KROMATID plans to deploy this funding to accelerate commercial expansion and enhance automation and throughput in its laboratory operations. The company will also invest in strategic hiring across scientific, operational, and customer-facing teams to meet increasing market demand and solidify its leadership position in genomic structural analysis. About KROMATIDKROMATID delivers next-generation genomic structural analysis solutions for gene and cell therapy developers, enabling precise detection of chromosomal structural rearrangements with unmatched clarity and resolution. By combining proprietary imaging and bioinformatics capabilities, KROMATID supports therapeutic innovation from discovery through regulatory approval. About BroadOak Capital PartnersBroadOak Capital Partners is a boutique financial institution that provides direct investment and investment banking services to companies in the life science tools, diagnostics, and biopharma services sectors. BroadOak has invested in more than 70 life sciences companies including over 35 exits. For more information, visit Media Contact:Amanda LadasGlobal Marketing ManagerKROMATIDaladas@ View original content to download multimedia: SOURCE KROMATID Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Pediatricians' association recommends COVID-19 vaccines for toddlers and some older children, breaking with CDC guidance
For 30 years, vaccine recommendations from the Centers for Disease Control and Prevention have aligned closely with those from the American Academy of Pediatrics, or AAP. But on Aug. 19, 2025, the AAP published new vaccine recommendations that diverge from those of the CDC. The pediatrician association's move comes on the heels of unprecedented changes made earlier this year by Robert F. Kennedy Jr., as head of the Department of Health and Human Services, in how the government approves and issues guidance on vaccines. The biggest difference is in the AAP's guidance around COVID-19 vaccines for children. This new guidance comes as COVID-19 cases are once again rising across the U.S. and many parents and providers are confused by unclear guidance from federal health authorities about whether children should be vaccinated. In a Q&A with The Conversation U.S., David Higgins, a pediatrician, preventive medicine physician and vaccine delivery researcher from the University of Colorado Anschutz Medical Campus, explains the new guidance and what it means for parents. Higgins is also a member of the American Academy of Pediatrics. What are the AAP's new vaccine recommendations? The AAP recommends that all children 6 to 23 months old receive a complete COVID-19 vaccine series, consistent with recommendations for this age group in previous years. For children and adolescents ages 2 to 18, the AAP now advises a single dose if they are at higher risk, a change from previous years, when vaccination was recommended for all in this age group. Children at higher risk include those who have certain chronic medical conditions, who live in long-term care or group settings, who have never been vaccinated, or who live with family members at high risk. The AAP also recommends that COVID-19 vaccines remain available for any child or adolescent whose parent wants them to be protected, regardless of risk status. In all cases, the most updated version of the vaccine should be used. How do these recommendations differ from CDC guidance? The difference is substantial. The CDC currently advises what it calls 'shared clinical decision-making' for children ages 6 months to 17 years who are not moderately or severely immunocompromised. This means the decision is left up to individual discussions between families and their health care providers, but the vaccine is not treated as a routine recommendation. These current guidelines were made after Kennedy bypassed the agency's normal independent review process. That framework can be confusing for families and difficult for providers to implement. By contrast, the AAP recommendations identify the ages and conditions where the risk is highest while also supporting vaccine availability for any families who want it. Why are they diverging? The AAP has been publishing vaccine guidance since the 1930s, long before the CDC or the Advisory Committee on Immunization Practices, an independent panel of experts that advises the CDC, existed. Since 1995, the two groups have generally issued essentially identical vaccine guidance. But this year, the federal government dismissed the advisory committee's panel of independent scientists and immunization experts, raising questions about the credibility of CDC guidance. At the same time, misinformation about vaccines continues to spread. In response, the AAP decided to publish independent recommendations based on its own review of the latest evidence. That review showed that although the risks for healthy older children have declined compared with the early years of the pandemic, young children and those with specific conditions remain especially vulnerable. Additionally, a review of evidence by an independent expert group called the Vaccine Integrity Project, also released on Aug. 19, 2025, confirmed that there are no new safety concerns and no decline in the effectiveness of COVID-19 vaccines. COVID-19 continues to cause hospitalizations and deaths in children and remains a leading cause of serious respiratory illness. Will parents be able to follow these recommendations? This is still unclear. The AAP recommendations do not automatically guarantee insurance coverage. By law, insurance plans and the federal Vaccines for Children program, which provides vaccines for eligible children who might not otherwise be vaccinated due to cost or lack of insurance, are tied to Advisory Committee on Immunization Practices recommendations. Unless insurers and policymakers act to align with the AAP recommendations, there is a risk that parents would be forced to pay the costs out of pocket. Vaccine supply may also be an issue. Currently, only two COVID-19 vaccines are available for children under 12. Moderna's vaccine is approved only for children with at least one high-risk condition, while Pfizer's authorization for younger children may not be renewed. If that happens, any remaining Pfizer doses for this age group may be unusable, leaving a shortfall in available vaccines for children. Finally, implementation may differ depending on the type of provider. Some vaccine providers, such as pharmacists, operate under policies tied strictly to CDC recommendations, which may make it harder to follow AAP's schedule unless rules are updated. What happens next? Parents and providers are likely to face continued confusion, just as COVID-19 cases rise as children return to school. Much will depend on whether the Advisory Committee on Immunization Practices updates its own recommendations at its upcoming meeting, expected in September, and whether pediatric COVID-19 vaccines remain available. Until then, parents can speak with their pediatricians to understand the best protection for their children. This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: David Higgins, University of Colorado Anschutz Medical Campus Read more: COVID-19 vaccines for kids are mired in uncertainty amid conflicting federal guidance RFK Jr. says annual COVID-19 shots no longer advised for healthy children and pregnant women – a public health expert explains the new guidance RFK Jr's shakeup of vaccine advisory committee raises worries about scientific integrity of health recommendations David Higgins volunteers as Vice President of the Colorado Chapter of the American Academy of Pediatrics and as a board member of Immunize Colorado. He was not involved in the development or publication of the American Academy of Pediatrics' immunization guidelines. The views and opinions expressed in this article are solely his own and do not represent those of the American Academy of Pediatrics. Solve the daily Crossword
Axios
14 minutes ago
- Axios
Why COVID-19 risk might be "very high" in these 5 states
Western states appear most at risk for COVID-19 cases right now, according to the Centers for Disease Control and Prevention, as the "stratus" variant and other versions of the virus circulate nationally. The big picture: Wastewater viral activity for COVID-19 has shifted from "moderate" to "low" this month, though some states in the West buck the trend. Driving the news: The CDC's map for COVID-19 wastewater monitoring showed these states had "very high" viral activity levels from Aug. 3 to Aug. 9, 2025: Utah Nevada Texas Alaska Hawaii Worth noting: California, Louisiana, Alabama, Florida, South Carolina and Connecticut all have "high" levels of viral activity, per data the CDC last updated on Aug. 14. What they're saying: "If you see increased wastewater viral activity levels, it might indicate that there is a higher risk of infection," the CDC says. Context: Nationally, viral activity dipped into the "low" range after the recent reemergence of the " stratus" COVID variant sent viral activity levels into the "moderate" phase. As of Aug. 12, the CDC said COVID infections "are growing or likely growing" in the majority of states. A dozen states are seeing high COVID test positivity rates compared to the rest of the country, according to recent CDC regional data. Still, case numbers are below peak pandemic levels. Current COVID-19 variants, like "stratus" What to know: These states are seeing a spike in viral activity and cases as the "nimbus" or NB.1.8.1 variant remains the top strand across the U.S., per CDC estimates from June. The LP.8.1 variant, a descendent of omicron, is the second most common, accounting for roughly one-third of cases. The XFG variant, also known as "stratus," is still third-highest with 14% of cases. However, according to CDC trends, the XFG variant made up 65% of the variants detected in wastewater nationwide as of Aug. 9. COVID symptoms for the current variants are similar to normal strains, such as fever, chills, cough, sore throat and congestion. However, there have been reports of "hoarseness" with the "stratus" variant and "razor-blade" sore throats for the "nimbus" variant. What's next with COVID? Rises in COVID-19 cases in the late summer and early fall aren't uncommon given children are headed back to school. What to watch: The CDC's next updates will likely point out how impactful the school year has been so far in terms of case positivity and viral activity.
